A phase IIA study of the topoisomerase I inhibitor, exatecan mesylate (DX-8951f), administered at two different dose schedules in patients with platinum- and taxane-resistant/refractory ovarian cancer.

A Clamp, M Adams, R Atkinson, E. Boven, AH Calvert, A Cervantes, T Ganesan, J Lotz, P Vasey, P Cheverton, GC Jayson

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)114-9
JournalGynecologic Oncology
Issue number1
Publication statusPublished - 2004

Cite this